James J. Burns & Company LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,970 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. RB Capital Management LLC grew its stake in shares of Pfizer by 6.7% in the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. grew its stake in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank grew its stake in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC grew its stake in shares of Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the last quarter. 67.80% of the stock is owned by institutional investors.
Pfizer Price Performance
Shares of NYSE PFE opened at $35.53 on Friday. Pfizer Inc. has a twelve month low of $35.35 and a twelve month high of $54.93. The firm has a market cap of $200.58 billion, a P/E ratio of 6.99, a PEG ratio of 1.18 and a beta of 0.61. The company has a 50 day moving average of $38.03 and a 200 day moving average of $41.57. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a yield of 4.62%. Pfizer’s payout ratio is currently 32.28%.
Insider Buying and Selling
In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Monday, May 8th. The stock was acquired at an average price of $38.58 per share, with a total value of $38,580.00. Following the transaction, the director now owns 6,000 shares in the company, valued at approximately $231,480. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several analysts recently issued reports on PFE shares. Barclays cut their target price on Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $47.00 to $40.00 in a research report on Thursday, June 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pfizer in a research report on Wednesday, May 17th. Morgan Stanley cut their price objective on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. Finally, Daiwa Capital Markets cut Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price objective on the stock. in a research report on Thursday, May 11th. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $46.67.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
